Adial Pharmaceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-1, initially filed on January 12, 2024. The company seeks to have the registration become effective on January 24, 2024, at 5:00 p.m. Eastern Time. This request was communicated through a letter to the SEC, confirming Adial Pharmaceuticals' understanding of its obligations under federal securities laws regarding the issuance of securities covered by the statement. The company has designated Leslie Marlow and Hank Gracin of Blank Rome LLP with the authority to modify or withdraw the acceleration request. The SEC has been asked to contact either Marlow or Gracin for any inquiries and to notify them once the acceleration has been granted. Cary Claiborne, the CEO of Adial Pharmaceuticals, signed the letter.

Adial Pharmaceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-1, initially filed on January 12, 2024. The company seeks to have the registration become effective on January 24, 2024, at 5:00 p.m. Eastern Time. This request was communicated through a letter to the SEC, confirming Adial Pharmaceuticals' understanding of its obligations under federal securities laws regarding the issuance of securities covered by the statement. The company has designated Leslie Marlow and Hank Gracin of Blank Rome LLP with the authority to modify or withdraw the acceleration request. The SEC has been asked to contact either Marlow or Gracin for any inquiries and to notify them once the acceleration has been granted. Cary Claiborne, the CEO of Adial Pharmaceuticals, signed the letter.